MX2023005846A - Composiciones para la administracion mejorada de los inhibidores de cgrp. - Google Patents
Composiciones para la administracion mejorada de los inhibidores de cgrp.Info
- Publication number
- MX2023005846A MX2023005846A MX2023005846A MX2023005846A MX2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A
- Authority
- MX
- Mexico
- Prior art keywords
- cgrp
- compositions
- inhibitor
- improved delivery
- subject
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 5
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 5
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se proporciona una composición farmacéutica que incluye un inhibidor peptídico relacionado con el gen de calcitonina (CGRP) y una cantidad que incrementa la absorción de una sustancia farmacéuticamente aceptable, tal como un carbohidrato tensioactivo. También se proporciona un método para incrementar la biodisponibilidad de un inhibidor peptídico relacionado con el gen de calcitonina (CGRP) en un sujeto, que incluye administrar vía oral para incrementar la biodisponibilidad del inhibidor de CGRP en el sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115789P | 2020-11-19 | 2020-11-19 | |
| US202063126550P | 2020-12-17 | 2020-12-17 | |
| PCT/US2021/059801 WO2022109077A1 (en) | 2020-11-19 | 2021-11-18 | Compositions for improved delivery of cgrp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005846A true MX2023005846A (es) | 2023-06-02 |
Family
ID=81709748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005846A MX2023005846A (es) | 2020-11-19 | 2021-11-18 | Composiciones para la administracion mejorada de los inhibidores de cgrp. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4247364A1 (es) |
| JP (1) | JP2023551146A (es) |
| KR (1) | KR20230088442A (es) |
| AU (1) | AU2021385052A1 (es) |
| CA (1) | CA3202137A1 (es) |
| IL (1) | IL302948A (es) |
| MX (1) | MX2023005846A (es) |
| WO (1) | WO2022109077A1 (es) |
| ZA (1) | ZA202304727B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
| US20160346198A1 (en) * | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| US10202435B2 (en) * | 2016-04-15 | 2019-02-12 | Alder Biopharmaceuticals, Inc. | Anti-PACAP antibodies and uses thereof |
| BR112021011546A2 (pt) * | 2019-01-20 | 2021-08-31 | Biohaven Pharmaceutical Holding Company Ltd. | Antagonistas de cgrp para tratamento de crises de enxaqueca |
| US20200360292A1 (en) * | 2019-05-16 | 2020-11-19 | Aegis Therapeutics, Llc | Oil-soluble drug containing compositions and methods of use thereof |
| WO2021062282A1 (en) * | 2019-09-25 | 2021-04-01 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
-
2021
- 2021-11-18 KR KR1020237016343A patent/KR20230088442A/ko active Search and Examination
- 2021-11-18 AU AU2021385052A patent/AU2021385052A1/en active Pending
- 2021-11-18 WO PCT/US2021/059801 patent/WO2022109077A1/en active Application Filing
- 2021-11-18 EP EP21895549.0A patent/EP4247364A1/en active Pending
- 2021-11-18 CA CA3202137A patent/CA3202137A1/en active Pending
- 2021-11-18 IL IL302948A patent/IL302948A/en unknown
- 2021-11-18 JP JP2023529881A patent/JP2023551146A/ja active Pending
- 2021-11-18 MX MX2023005846A patent/MX2023005846A/es unknown
-
2023
- 2023-04-24 ZA ZA2023/04727A patent/ZA202304727B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021385052A9 (en) | 2024-05-02 |
| JP2023551146A (ja) | 2023-12-07 |
| WO2022109077A1 (en) | 2022-05-27 |
| ZA202304727B (en) | 2023-12-20 |
| CA3202137A1 (en) | 2022-05-27 |
| IL302948A (en) | 2023-07-01 |
| KR20230088442A (ko) | 2023-06-19 |
| AU2021385052A1 (en) | 2023-06-01 |
| EP4247364A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304727B (en) | Compositions for improved delivery of cgrp inhibitors | |
| ECSP088403A (es) | Formulacion farmaceutica de absorción oral y su método de administracion | |
| AR048891A2 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
| TR201820559T4 (tr) | Azelastin içeren kompozisyonlar ve bunların kullanım metotları. | |
| AR062320A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| CL2017003208A1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| MX2022007336A (es) | Composiciones farmaceuticas intranasales de inhibidores de cgrp. | |
| TN2009000504A1 (en) | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray | |
| PH12021551371A1 (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| MX2022008914A (es) | Compuestos terapeuticos, formulaciones y usos de los mismos. | |
| Choi et al. | Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin | |
| MX2023007335A (es) | Composiciones para la administracion mejorada de inhibidores del cgrp. | |
| WO2020141828A3 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
| CO5540295A2 (es) | Comprimido para tragar que comprende paracetamol | |
| CO2021011046A2 (es) | Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica | |
| MX2009006699A (es) | Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos. | |
| EP2662077B1 (en) | Effervescent compositions containing n-acetylcysteine | |
| MX2009005218A (es) | Composicion farmaceutica anticonvulsiva transnasal. | |
| RU2010129409A (ru) | Способ лечения псороптоза кроликов и отодектоза плотоядных животных | |
| KR20110119108A (ko) | 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물 | |
| PH12015501389A1 (en) | Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide | |
| US9968648B2 (en) | Peptide or protein stabilizing formulation | |
| ZA200408929B (en) | Process for the preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improve bioavalability | |
| AR114587A1 (es) | Formulaciones de epinefrina en aerosol | |
| Nelson et al. | Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV co-infection |